184 related articles for article (PubMed ID: 31280234)
1. Cognitive Functioning and Psychological Well-being in Breast Cancer Patients on Endocrine Therapy.
Biro E; Kahan Z; Kalman J; Rusz O; Pakaski M; Irinyi T; Kelemen G; Dudás R; Drotos G; Hamvai C
In Vivo; 2019; 33(4):1381-1392. PubMed ID: 31280234
[TBL] [Abstract][Full Text] [Related]
2. Self-reported cognitive functioning in postmenopausal breast cancer patients before and during endocrine treatment: findings from the neuropsychological TEAM side-study.
Schilder CM; Seynaeve C; Linn SC; Boogerd W; Beex LV; Gundy CM; Nortier JW; van de Velde CJ; van Dam FS; Schagen SB
Psychooncology; 2012 May; 21(5):479-87. PubMed ID: 21351188
[TBL] [Abstract][Full Text] [Related]
3. Neuropsychological functioning in postmenopausal breast cancer patients treated with tamoxifen or exemestane after AC-chemotherapy: cross-sectional findings from the neuropsychological TEAM-side study.
Schilder CM; Eggens PC; Seynaeve C; Linn SC; Boogerd W; Gundy CM; Beex LV; Van Dam FS; Schagen SB
Acta Oncol; 2009; 48(1):76-85. PubMed ID: 18777410
[TBL] [Abstract][Full Text] [Related]
4. Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial.
Fallowfield L; Cella D; Cuzick J; Francis S; Locker G; Howell A
J Clin Oncol; 2004 Nov; 22(21):4261-71. PubMed ID: 15514369
[TBL] [Abstract][Full Text] [Related]
5. Physical activity and body composition, body physique, and quality of life in premenopausal breast cancer patients during endocrine therapy--a feasibility study.
Hojan K; Molińska-Glura M; Milecki P
Acta Oncol; 2013 Feb; 52(2):319-26. PubMed ID: 23193959
[TBL] [Abstract][Full Text] [Related]
6. Long term effects of extended adjuvant endocrine therapy on quality of life in breast cancer patients.
Kool M; Fontein DB; Meershoek-Klein Kranenbarg E; Nortier JW; Rutgers EJ; Marang-van de Mheen PJ; van de Velde CJ
Breast; 2015 Jun; 24(3):224-9. PubMed ID: 25704982
[TBL] [Abstract][Full Text] [Related]
7. Does hormone therapy for the treatment of breast cancer have a detrimental effect on memory and cognition? A pilot study.
Jenkins V; Shilling V; Fallowfield L; Howell A; Hutton S
Psychooncology; 2004 Jan; 13(1):61-6. PubMed ID: 14745746
[TBL] [Abstract][Full Text] [Related]
8. Cognitive limitations associated with tamoxifen and aromatase inhibitors in employed breast cancer survivors.
Breckenridge LM; Bruns GL; Todd BL; Feuerstein M
Psychooncology; 2012 Jan; 21(1):43-53. PubMed ID: 20967847
[TBL] [Abstract][Full Text] [Related]
9. Health-related quality of life, psychological distress, and adverse events in postmenopausal women with breast cancer who receive tamoxifen, exemestane, or anastrozole as adjuvant endocrine therapy: National Surgical Adjuvant Study of Breast Cancer 04 (N-SAS BC 04).
Takei H; Ohsumi S; Shimozuma K; Takehara M; Suemasu K; Ohashi Y; Hozumi Y
Breast Cancer Res Treat; 2012 May; 133(1):227-36. PubMed ID: 22234519
[TBL] [Abstract][Full Text] [Related]
10. Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy.
van Dam FS; Schagen SB; Muller MJ; Boogerd W; vd Wall E; Droogleever Fortuyn ME; Rodenhuis S
J Natl Cancer Inst; 1998 Feb; 90(3):210-8. PubMed ID: 9462678
[TBL] [Abstract][Full Text] [Related]
11. Randomized trial of adjuvant tamoxifen and/or goserelin in premenopausal breast cancer--self-rated physiological effects and symptoms.
Nystedt M; Berglund G; Bolund C; Brandberg Y; Fornander T; Rutqvist LE
Acta Oncol; 2000; 39(8):959-68. PubMed ID: 11207003
[TBL] [Abstract][Full Text] [Related]
12. Effects of surgical and adjuvant therapies for breast cancer on sexuality, cognitive functions, and body weight.
Biglia N; Moggio G; Peano E; Sgandurra P; Ponzone R; Nappi RE; Sismondi P
J Sex Med; 2010 May; 7(5):1891-900. PubMed ID: 20233281
[TBL] [Abstract][Full Text] [Related]
13. [A Structural Model for Chemotherapy Related Cognitive Impairment and Quality of Life in Breast Cancer Patients].
Lee JR; Oh PJ
J Korean Acad Nurs; 2019 Aug; 49(4):375-385. PubMed ID: 31477668
[TBL] [Abstract][Full Text] [Related]
14. Health-related quality of life in early breast cancer.
Groenvold M
Dan Med Bull; 2010 Sep; 57(9):B4184. PubMed ID: 20816024
[TBL] [Abstract][Full Text] [Related]
15. Cognitive functioning during long-term tamoxifen treatment in postmenopausal women with breast cancer.
Boele FW; Schilder CM; de Roode ML; Deijen JB; Schagen SB
Menopause; 2015 Jan; 22(1):17-25. PubMed ID: 24977455
[TBL] [Abstract][Full Text] [Related]
16. The effects of hormone therapy on cognition in breast cancer.
Shilling V; Jenkins V; Fallowfield L; Howell T
J Steroid Biochem Mol Biol; 2003 Sep; 86(3-5):405-12. PubMed ID: 14623538
[TBL] [Abstract][Full Text] [Related]
17. Pre- and postmenopausal high-risk women undergoing screening for ovarian cancer: anxiety, risk perceptions, and quality of life.
Hensley ML; Robson ME; Kauff ND; Korytowsky B; Castiel M; Ostroff J; Hurley K; Hann LE; Colon J; Spriggs D
Gynecol Oncol; 2003 Jun; 89(3):440-6. PubMed ID: 12798709
[TBL] [Abstract][Full Text] [Related]
18. Subjective and objective cognitive functioning among patients with breast cancer: effects of chemotherapy and mood symptoms.
Hsu YH; Chen VC; Hsieh CC; Weng YP; Hsu YT; Hsiao HP; Wang WK; Chen HM; Weng JC; Wu SI; Gossop M
Breast Cancer; 2021 Jan; 28(1):236-245. PubMed ID: 33030667
[TBL] [Abstract][Full Text] [Related]
19. Complete estrogen blockade for the treatment of metastatic and early stage breast cancer.
Michaud LB; Buzdar AU
Drugs Aging; 2000 Apr; 16(4):261-71. PubMed ID: 10874521
[TBL] [Abstract][Full Text] [Related]
20. The role of depression in the relationship between cognitive decline and quality of life among breast cancer patients.
Park JH; Jung YS; Jung YM; Bae SH
Support Care Cancer; 2019 Jul; 27(7):2707-2714. PubMed ID: 30498990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
